Odonate Therapeutics Inc (NASDAQ:ODT) CEO Kevin C. Tang bought 769,231 shares of the stock in a transaction on Wednesday, June 26th. The stock was purchased at an average price of $26.00 per share, for a total transaction of $20,000,006.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link.
NASDAQ:ODT traded down $0.02 during mid-day trading on Friday, hitting $33.17. 121,196 shares of the company’s stock traded hands, compared to its average volume of 178,235. The firm’s 50 day moving average price is $30.53. The company has a market capitalization of $887.20 million, a price-to-earnings ratio of -9.11 and a beta of 1.68. Odonate Therapeutics Inc has a 12 month low of $11.54 and a 12 month high of $37.99.
Odonate Therapeutics (NASDAQ:ODT) last posted its quarterly earnings results on Thursday, April 25th. The company reported ($1.16) EPS for the quarter, beating the consensus estimate of ($1.24) by $0.08. On average, sell-side analysts forecast that Odonate Therapeutics Inc will post -4.59 earnings per share for the current year.
Several analysts recently weighed in on the company. Zacks Investment Research upgraded HB Fuller from a “sell” rating to a “hold” rating in a research note on Wednesday, July 3rd. Cowen restated a “buy” rating on shares of Odonate Therapeutics in a research note on Monday, June 3rd. Finally, ValuEngine downgraded Acceleron Pharma from a “strong-buy” rating to a “buy” rating in a research note on Thursday, April 18th.
About Odonate Therapeutics
Odonate Therapeutics, Inc, a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with locally advanced or metastatic breast cancer. The company was founded in 2013 and is based in San Diego, California.
See Also: Buy Rating
Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.